Dr Stefania Oliva speaks to ecancer about minimum residual disease techniques in myeloma. Initially, she talks about the best techniques for measuring MRD in clinical practice and then she discusses the use of MRD in clinical trials.

Dr Oliva then talks about the different treatment methods that can be given to patients depending on whether they are MRD positive or negative. She concludes by saying that MRD should be used as a surrogate for survival in clinical trials.